Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients With or Without Comorbidities (RIO-Europe).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2009
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms RIO-EUROPE
- Sponsors Sanofi
- 12 May 2009 Actual end date (Jun 2004) added as reported by ClinicalTrials.gov.
- 06 Jun 2008 Results presented at the 68th Annual Scientific Sessions of the American Diabetes Association.
- 17 Oct 2006 New trial record.